TY - JOUR
T1 - Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts
AU - Scalea, Joseph R.
AU - Barth, Rolf N.
AU - Munivenkatappa, Raghava
AU - Philosophe, Benjamin
AU - Cooper, Matthew
AU - Whitlow, Victoria
AU - Lamattina, John C.
N1 - Publisher Copyright:
Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2015/6/6
Y1 - 2015/6/6
N2 - Background. There is a paucity of data regarding long-term renal graft survival in hepatitis C virus positive (HCV+) patients. We analyzed our institution's experience with HCV+ renal transplantation and factors contributing to subsequent renal graft failure. Methods. We analyzed 1,679 adult, deceased donor, single-organ renal transplants occurring between 2000 and 2012. Recipient and donor demographics, HCV serostatus, and graft outcome and function were evaluated. Results. Of 1,679 patients, 195 HCV+ recipients (R+) received renal transplants from HCV+ donors (D+), in contrast to 1,418 HCV negative (HCV-) recipients (R-) who received grafts from HCV- donors (D-), and 66 R+ patients who received D- kidneys. Death-censored graft survival in the R+/D+ population was better than graft survival for R+/D- patients, despite R+/D+ patients having higher rates of hypertension and African Americans. Waitlist times for patients accepting HCV+ grafts was 318 days (for R+/D+ patients) versus 613 days (R-/D-) or 570 days (R+/D-). On multivariate analysis, waitlist times were independently predictive of graft failure. Conclusion. R+/D+ patients spent less time on the transplant waitlist, which contributed to improved death censored graft survival when compared with R+/D- patients.
AB - Background. There is a paucity of data regarding long-term renal graft survival in hepatitis C virus positive (HCV+) patients. We analyzed our institution's experience with HCV+ renal transplantation and factors contributing to subsequent renal graft failure. Methods. We analyzed 1,679 adult, deceased donor, single-organ renal transplants occurring between 2000 and 2012. Recipient and donor demographics, HCV serostatus, and graft outcome and function were evaluated. Results. Of 1,679 patients, 195 HCV+ recipients (R+) received renal transplants from HCV+ donors (D+), in contrast to 1,418 HCV negative (HCV-) recipients (R-) who received grafts from HCV- donors (D-), and 66 R+ patients who received D- kidneys. Death-censored graft survival in the R+/D+ population was better than graft survival for R+/D- patients, despite R+/D+ patients having higher rates of hypertension and African Americans. Waitlist times for patients accepting HCV+ grafts was 318 days (for R+/D+ patients) versus 613 days (R-/D-) or 570 days (R+/D-). On multivariate analysis, waitlist times were independently predictive of graft failure. Conclusion. R+/D+ patients spent less time on the transplant waitlist, which contributed to improved death censored graft survival when compared with R+/D- patients.
UR - http://www.scopus.com/inward/record.url?scp=84930535959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930535959&partnerID=8YFLogxK
U2 - 10.1097/TP.0000000000000479
DO - 10.1097/TP.0000000000000479
M3 - Article
C2 - 25340605
AN - SCOPUS:84930535959
SN - 0041-1337
VL - 99
SP - 1192
EP - 1196
JO - Transplantation
JF - Transplantation
IS - 6
ER -